Carlsmed, Inc. — Form 8-K Summary
Event date: September 24, 2026; the report describes events through September 29 and was signed September 30, 2026. This is a management transition filing, not a periodic financial-results report.
Business context and financial information
Carlsmed announced a change in its chief financial officer. The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance figures, and no comparable-period financial data or company guidance.
Management transition and compensation
- Leo Greenstein’s CFO service ended September 25, 2026. The company said his departure did not result from a disagreement regarding accounting, financial disclosures, or internal controls.
- Under his separation agreement, Greenstein is to receive $500,000 in salary continuation, a prorated 2026 incentive award based on performance targets, and up to 12 months of COBRA premiums. The filing says these benefits are consistent with his previously disclosed employment agreement.
- His agreement also provides accelerated vesting of specified equity awards, including 32,856 early-exercised restricted shares, 19,176 shares subject to an existing option, 26,786 additional shares subject to a 2025 option, and 11,244 RSUs. The remaining unvested awards are forfeited. The vested portion of the 2025 option may be exercised through the first anniversary of his separation date.
- Greenstein will provide advisory services through December 31, 2026, for a total fee of $60,000, prorated if the agreement ends early.
- Richard Heppenstall was appointed CFO effective September 28, 2026. His initial base salary is $500,000, with a target annual cash incentive of 60% of base salary (equivalent to $300,000 at target), prorated for 2026.
- Heppenstall received inducement equity awards with stated values of $1.4 million for stock options and $1.4 million for RSUs. Options vest over four years and RSUs over three years, subject to continued service.
- The company may reimburse up to $150,000 for relocation and transition expenses, subject to conditions. Heppenstall’s agreement also provides specified severance and equity-acceleration benefits in certain termination circumstances, including enhanced benefits during a defined change-in-control period.
Outlook, risks, and unusual items
The filing gives no business outlook or assessment of expected operating results. The disclosed items are executive-transition costs and commitments, including severance, advisory fees, equity vesting, new-hire compensation, and relocation reimbursement. Payment of Greenstein’s separation benefits is conditioned on a release and other agreement requirements; relocation reimbursement is subject to residence and repayment conditions. The filing does not quantify the total accounting expense or cash-flow effect of these arrangements.
Facts investors should verify
- Review the filed separation, advisory, employment, relocation, and equity agreements for detailed terms and conditions.
- Confirm the financial-statement treatment and timing of severance, advisory, equity-compensation, and relocation costs.
- Check subsequent filings for updates to CFO responsibilities, transition costs, or any changes to the disclosed arrangements.
- The body identifies the departing CFO as “Leo Greenstein,” while the exhibit list names “Leonard Greenstein”; verify the name and exhibit references in the filed agreements.